Symptoms of overdosage may include nausea, vomiting, drowsiness, restlessness excitement, ataxia, respiratory depression and occasionally convulsions and hyperpyrexia. In cases of severe overdosage, the stomach should be emptied by aspiration and lavage. The patient should be kept quiet to minimise excitation which occurs particularly in children. The specific narcotic antagonist naloxone may be used to reverse any respiratory depression. Convulsions may be controlled with intravenous diazepam. Otherwise treatment should be symptomatic and supportive.
36 months
Hypersensitivity to any of the ingredients, liver disease, ventilatory failure and porphyria.
Not applicable.
Hyetellose
Glycerol
Liquid sugar
Citric acid monohydrate
Sodium citrate
Sodium benzoate
Quinoline yellow
Patent Blue V
Alcohol
Grenadine flavour 514485E GIV (contains propylene glycol)
Purified water
Oral Solution
May occasionally cause nausea, vomiting, drowsiness, skin rashes and anticholinergic side effects such as dryness of the mouth, constipation, urinary retention and blurred vision. May also cause elation or depression, irritability and nightmares.
Immune system disorders: hypersensitivity reactions, anaphylaxis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Not applicable.
For the symptomatic relief of dry, ticklish and unproductive coughs.
For oral administration.
Pholcodine is a cough suppressant with mild sedative but little analgesic action.
Diphenhydramine has antihistamine properties with a pronounced sedative action.
Pholcodine is readily absorbed from the gastrointestinal tract. It can relieve local irritation of the respiratory tract for about 4 to 5 hours.
Peak plasma levels of diphenhydramine hydrochloride occur 2 to 4 hours after administration. Diphenhydramine is about 85 - 98% bound to plasma proteins. The plasma half life ranges from 2.4 to 8 hours.
Diphenhydramine undergoes extensive pre-systemic metabolism which results in 50% metabolism of an oral dose. The major route of elimination is in the urine, largely as metabolites with very little unchanged drug present.
15 September 2015
Boots Nirolex Night Time Cough Relief Linctus
Almus Night Time Cough Relief Linctus
Boots Night Cough Relief Oral Solution
The Boots Company PLC
1 Thane Road West
Nottingham
NG2 3AA
Trading as: BCM
Do not store above 25°C.
1. A 50ml, 100ml, 125ml, 150ml, 200ml or 250ml glass bottle either with a child resistant polypropylene cap without a liner or a roll on pilfer proof cap with a liner.
2. A 50ml, 100ml, 125ml, 150ml, 200ml, or 250ml amber glass bottle either with a child resistant polypropylene cap without a liner or a roll on pilfer proof cap with a liner.
3. A 50ml, 100ml, 125ml, 150ml, 200ml or 250ml amber PET bottle fitted with a child resistant polypropylene cap and an expanded polyethylene liner.
PL 00014/0230
|
Active ingredient |
mg/5ml |
| Diphenhydramine hydrochloride Ph Eur | 12.5 |
| Pholcodine Ph Eur | 3.75 |
Children under 12 years should not be given this medicine.
Cough suppressants may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis.
This medicine should be used with care in conditions such as closed angle glaucoma, urinary retention, prostatic hypertrophy or pyloroduodenal obstruction. Caution should also be observed in patients with epilepsy and severe cardiovascular disorders.
As pholcodine is a sedative, caution is needed in those patients who have airway disease e.g. asthma, chronic obstructive pulmonary disease (COPD) and ventilatory insufficiency, as respiratory depression may occur. Caution is also needed in patients with kidney disease or a history of drug abuse.
Warning: May cause drowsiness. If affected do not drive or operate machinery.
Avoid alcoholic drink.
Do not exceed the stated dose.
If symptoms persist for longer than 5 days talk to your doctor.
Keep all medicines out of the reach of children.
Information related specifically to the excipients in this formulation
Sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Each 20ml dose contains 9g sucrose.
Ethanol: Each 20ml dose contains 0.8g alcohol (ethanol), equivalent to 20ml beer or 8ml wine. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breastfeeding women, children and high-risk groups such as patients with liver disease or epilepsy.
Sodium: Each 20ml dose contains 41mg of sodium. To be taken into consideration by patients on a controlled sodium diet.
May cause drowsiness. If affected do not drive or operate machinery.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
- The medicine is likely to affect your ability to drive
- Do not drive until you know how the medicine affects you
- It is an offence to drive while under the influence of this medicine
- However, you would not be committing an offence (called a 'statutory defence') if:
-The medicine has been prescribed to treat a medical or dental problem and
-You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
-It was not affecting your ability to drive safely
Adults and Children over 12 years: 20ml (4 teaspoonfuls) at bedtime.
Children under 12 years: Not recommended.
Elderly: There is no need for dosage reduction.
Not applicable.
February 1981
